19 / 25
Page 47
Notes:
allied
academies
February 25-26, 2019 | Paris, France
13
th
World Cancer Congress
Journal of Medical Oncology and Therapeutics | Volume 4
Effective number of cycle and dose in metastatic castrated resistant Prostatic Cancer in Sudanese patients
Ehssan M Alnazir Ahmed
Omdurman Islamic University (OIU), Sudan
P
rostate cancer remain the most common cancer in men
worldwide. The initial treatment of choice for prostate
cancer is androgen deprivation. If resistant develop then
Docetaxel becomes the mainstay therapy for patients with
metastatic castrated resistant prostate cancer.
The main objectives of this study is to evaluate the benefit
of docetaxel in patients with metastatic castrated resistant
prostate cancer (mCRPC) after initial good response to first
line hormonal therapy and determine the effective number of
cycles and doses of doectaxel.
The study design was analytic retrospective study during the
years 2017-2013 in the area radioisotope center of Khartoum
(RICK), with the populationmCRPC. The data collectedwas from
RICK record. Inclusion criteria were any prostatic cancer patient
become castrated resistant and now on docetaxel therapy.
Procedure was followed with patient files using a Sample size
of 60 patients.
To conclude, we retrospectively collected 60 patients receiving
varying numbers of docetaxel plus prednislone and analyzed
the clinical outcomes including performance status, prostate-
specific antigen (PSA) response and pain. According to this study
we found that docetaxel has effective role in the treatment of
mCRPC patients with optimal number of cycles 6 to 8 every 3
weeks and dose of 75 mg.
e:
ihssan61@hotmail.com